to the web site of the Molecular Medicine Group. The Group is led
by John McVey and was established in May 2008 at the
Research Institute (London). The Group is now located in the Faculty of Health and Medical Sciences
at the University of Surrey, where John is Professor of Cardiovascular Biology.
research focuses on the regulation of blood
coagulation and the role the coagulation factors play in normal
physiology and in the pathophysiology of disease. Blood
coagulation is normally initiated in response to injury in order
to preserve the integrity of the vascular system. The ability to stem
the loss of body fluids from the site of injury is a basic defence
mechanism that is essential for the survival of any multicellular
organism. The critical need to rapidly form a stable, localised clot
in response to injury must be balanced with the need to maintain blood
flow within the vessel. In addition, the process of blood coagulation
must be intimately linked with cellular processes that ultimately
lead to controlled clot removal and wound/tissue repair.
Inherited defects and/or deficiencies of the blood
coagulation factors lead to impaired clot formation and bleeding.
The most common bleeding disorders are X-linked deficiencies of factor
VIII (haemophilia A) and factor IX (haemophilia B), which affect 1:5000
and 1:30000 male births, respectively.
In contrast, the pathological consequences of inappropriate coagulation
include thrombotic events following atherosclerotic plaque rupture
and disseminated intravascular coagulation seen in sepsis. Cardiovascular
disease, of which thrombosis is a major contributing factor, is the
main cause of death in the UK, accounting for 300,000 deaths in 1996,
costing the health care system £1,600 million.
and future work
See the Research page for a description
of these projects.
- Studies on the initiation of blood coagulation in disease models
- Development of novel anticoagulant strategies »
. . .
- Gene therapy for inherited coagulation factor disorders »
. . .
- Genetic and functional studies in inherited coagulation disorders
. . .
- Role of coagulation factors in modulating delivery of adenoviral
gene therapy vectors »
. . .